Related Experiment Video

Updated: May 22, 2026

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals
07:39

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

Published on: June 25, 2018

Selective estrogen receptor modulation in pancreatic β-cells and the prevention of type 2 diabetes

Joseph Tiano1, Franck Mauvais-Jarvis

  • 1Department of Medicine, Division of Endocrinology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Islets
|May 1, 2012
PubMed

Insights

The female hormone 17β-estradiol (E2) prevents type 2 diabetes (T2D) by reducing fat synthesis in pancreatic beta cells. Selective estrogen receptor modulators (SERMs) may offer similar protection, suggesting new T2D prevention strategies.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Molecular Biology

Background:

  • Type 2 diabetes (T2D) is linked to beta-cell failure, often exacerbated by lipotoxicity.
  • The hormone 17β-estradiol (E2) has demonstrated protective effects against beta-cell failure in T2D models.
  • E2's protective mechanisms involve suppressing fatty acid and glycerolipid synthesis within islets.

Purpose of the Study:

  • To investigate the role of selective estrogen receptor modulators (SERMs) in beta-cell function and lipogenesis.
  • To determine if SERMs can replicate the anti-lipogenic effects of E2 in beta cells.
  • To explore the potential of SERMs for T2D prevention, particularly in postmenopausal women.

Main Methods:

  • Utilized INS-1 insulin-secreting cells, a rodent beta-cell model.
  • Administered Raloxifene, a selective estrogen receptor modulator (SERM).
  • Assessed both nuclear estrogen receptor (ER)-dependent actions and triglyceride accumulation to evaluate ER agonistic and antagonistic effects.

Main Results:

  • Raloxifene exhibited dual activity: acting as an ER antagonist for nuclear, estrogen response element (ERE)-dependent actions.
  • Raloxifene also functioned as an ER agonist, effectively suppressing triglyceride accumulation in beta cells.
  • These findings suggest that SERMs with ER agonistic properties in beta cells could be beneficial.

Conclusions:

  • SERMs like Raloxifene present a potential therapeutic avenue for T2D prevention by mitigating beta-cell lipotoxicity.
  • The dual ER agonistic and antagonistic actions of SERMs in beta cells warrant further investigation.
  • Future research should focus on novel SERMs to confirm their efficacy in preventing T2D, especially in the context of postmenopause.

More Related Videos

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...